Actinium Pharmaceuticals Inc (NYSEMKT: ATNM)
Actinium pharmaceuticals (ATNM) on Tuesday announced the hiring of Steven Price, to serve as Vice President, Clinical and Commercial Strategy.
Mr. Price, an industry veteran will be responsible for leading the development and optimized programs for Iomab-B, including initiatives targeted at patients, physicians, and payors designated to support clinical development and pre-commercialization efforts.
Key Hiring Adds Depth To An Already Robust Management Team
Mr. Price will bring extensive industry experience to ATNM, delivering over 30 years of marketing and strategic leadership experience to the company. His work specializes in the oncology field with most recent experiences in immunotherapy focused on hematology at Merck and antibody-based therapeutics at Imclone Systems.
Prior to joining the ATNM team, Mr. Price most recently served as the Global Disease Lead at Merck, where he focused on Keytruda, an anti-PD-1 immuno-oncology antibody. In that capacity, he served as the commercial lead on the product development team and was responsible for maximizing physician acceptance, KOL development, market penetration, and new indication launch uptake. Additional experience includes a vast knowledge of pre-launch strategies, pre-market evaluations, strategy development, and strategic and product implementation initiatives.
At Imclone, Mr. Price served as the Associate Vice President, Global New Products Strategic Marketing, where he was responsible and successful at facilitating all commercial aspects of the new product pipeline. Imclone subsequently became a wholly owned subsidiary of Eli Lilly.
Commenting on the hiring, ATNM Executive Chairman, Sandeth Seth, stated, “Steve’s hiring represents another significant step in Actinium’s growth and one that I am most excited about. Steve brings to Actinium a significant amount of knowledge and experience specific to hematology and also has deep relationships that he curated in his 30 years in this field. I look forward to working with Steve and the rest of the Actinium team in building a great company that is focused on improving outcomes for patients.”
ATNM is efficiently executing on their clinical initiatives and continue to deliver impressive results. A biopharmaceutical company that is developing innovative targeted therapies for patients with cancers lacking an effective treatment option, ATNM’s proprietary platform is progressing diligently, utilizing monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill these cells safely and effectively.
ATNM’s lead product, Iomab-B is being designed and developed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, most commonly referred to as a bone marrow transplant. Currently, a bone marrow transplant serves as the only current potential cure for patients with blood-borne cancers, which often requires the use of chemotherapeutic treatments and total body irradiation that often results in significant toxicities.
ATNM is progressing in its single pivotal, 150-patient multi-center phase III clinical study of Iomab-B in patients with relapsed or refractory acute multiple myeloma in patients 55 years of age and over. Interim results are expected during 2017.
ATNM has a second promising clinical stage candidate, Actimab-A. Actimab-A is currently advancing its study in a multi-center, open label, 53 patient phase II trial for patients newly diagnosed with AML and are 60 years of age or older. Endpoints for this study are working to demonstrate the ability to induce remissions in elderly patients with AML who lack effective treatment options, especially for patients that may not have the ability to tolerate standard treatment options that introduce toxicities into the body.
Actimab-M, another product candidate, is being developed and studied in patients with relapsed or refractory multiple myeloma in a phase I clinical trial. ATNM is utilizing its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225, that are directed at various cancers that are blood-borne or form solid tumors in the body.
For continued breaking news coverage on Actinium pharmaceuticals, stay with CNA Finance, your source for all things ATNM.
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!